AVBP News

Eleven IPOs raised a combined $3.8 billion in January, the busiest month for both $100+ million and $1+ billion IPOs since late 2021. Six offerings raised $100 million or more, led by two billion-dollar deals: sports gear maker Amer Sports (AS) and Kazakhstani "super app" Kaspi.kz (KSPI). Remaining activity came from small, primarily China-based...read more

Seven IPOs priced this past week, led by three that raised $100+ million. After upwardly revising the terms earlier in the week, CG Oncology (CGON) further upsized the offering and priced above the range to raise $380 million at a $1.3 billion market cap. Its sole clinical asset is initially in development for a subclass of bladder cancer and is currently in an...read more

ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for EGFR-mutated lung cancer, raised $175 million by offering 9.7 million shares at $18, within the range of $17 to $19. The company offered 1.4 million more shares than anticipated. ArriVent Biopharma's lead candidate, furmonertinib, is an investigational, novel, epidermal growth factor receptor (EGFR)...read more

ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, announced terms for its IPO on Monday. The Newtown Square, PA-based company plans to raise $150 million by offering 8.3 million shares at a price range of $17 to $19. At the midpoint of the proposed range, ArriVent Biopharma would command a fully diluted market value of $585 million. ArriVent...read more